Cat. No. | Product name | CAS No. |
DCAPI1325 |
Rifabutin (Mycobutin)
Rifabutin (Mycobutin) |
72559-06-9 |
DC7265 |
Rigosertib
Featured
Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM; shows 30-fold greater selectivity against PLK2 and no activity to PLK3. |
1225497-78-8 |
DC7266 |
Rilpivirine(R 278474, TMC 278)
Featured
Rilpivirine(R 278474, TMC 278) is a type of anti-HIV medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI). |
500287-72-9 |
DC7268 |
Risperidone(R 64 766)
Risperidone(R 64 766) is a serotonin 5-HT2 receptor blocker(Ki= 0.16 nM) and a potent dopamine D2 receptor antagonist(Ki= 1.4 nM). |
106266-06-2 |
DC9475 |
Ritonavir
Featured
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS,showed potent activity against COVID-19(SARS-COV-2) . |
155213-67-5 |
DC5108 |
BAY 59-7939 (Rivaroxaban)
Featured
Rivaroxaban (Xarelto; BAY 59-7939) is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembolic disorders. |
366789-02-8 |
DCAPI1435 |
Rivastigmine tartrate
Rivastigmine hydrogen tartrate is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer’s type and Parkinson's disease. |
129101-54-8 |
DC5146 |
RN486
Featured
RN-486 is a Bruton's tyrosine kinase (Btk) inhibitor. |
1242156-23-5 |
DC9454 |
Ro 28-1675
Ro 28-1675 (Ro 0281675) is a potent allosteric GK activator with a SC1.5 value of 0.24± 0.0019 uM. |
300353-13-3 |
DC9666 |
Ro 46-2005
Featured
Ro 46-2005 is a novel synthetic non-peptide endothelin receptor antagonist, inhibits the specific binding of 125I-ET-1 to human vascular smooth muscle cells (ETA receptor) with IC50 of 220 nM. |
150725-87-4 |
DC7933 |
Ro 48-8071 fumarate
Featured
Ro 48-8071 fumarate is an inhibitor of OSC(Oxidosqualene cyclase; IC50=6.5 nM) that has low-density lipoprotein (LDL) cholesterol lowering activity. |
189197-69-1 |
DC8215 |
RO4929097
Featured
RO4929097 is a γ secretase inhibitor with IC50 of 4 nM, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively. |
847925-91-1 |
DC10583 |
RO 5028442
Featured
RO5028442 is a highly potent and selective Brain-Penetrant Vasopressin 1a (V1a) receptor antagonist with Kis of 1 nM (hV1a) and 39 nM (mV1a). |
920022-47-5 |
DC7489 |
RO5126766(CH5126766)
RO5126766(CH5126766) is a Raf/MEK dual kinase inhibitor. |
946128-88-7 |
DC12353 |
Roniciclib (BAY 1000394)
Roniciclib is an orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor, with IC50s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9. |
1223498-69-8 |
DC4124 |
ROSCOVITINE(Seliciclib)
Featured
Roscovitine (Seliciclib, CYC202, R-roscovitine) is a potent and selective CDK inhibitor for Cdc2/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p53 with IC50 of 0.65 μM, 0.7 μM, 0.7 μM and 0.16 μM, respectively. |
186692-46-6 |
DC9084 |
Rosiglitazone base
Rosiglitazone(BRL-49653) is a high-affinity selective agonist of the peroxisome proliferator-activated receptor-γ(PPARγ). |
122320-73-4 |
DC7490 |
Rostafuroxin
Featured
Rostafuroxin: an ouabain-inhibitor counteracting specific forms of hypertension. |
156722-18-8 |
DC5015 |
Rotigotine Hydrochloride
Rotigotine is dopamine D2 and D3 receptor agonist. Ki values are 13 and 0.71 nM for D2 and D3 respectively. Rotigotine also has significant affinity for 5-HT1A and adrenergic α2B receptors. Rotigotine exhibits antiparkinsonian acitivity. |
125572-93-2 |
DC11671 |
RPL-554
RPL-554 (LS-193855, RPL554) is a potent, orally available, dual PDE3/PDE4 inhibitor with IC50 of 0.4 nM and 1479 nM, respectively. |
298680-25-8 |
DC10036 |
RRx-001
Featured
RRx-001 is a novel epigenetic modulator with potential radiosensitizing activity. It inhibits glucose 6-phosphate dehydrogenase(G6PD) in human tumor cells, binds hemoglobin and drives RBC-mediated redox reactions under hypoxia. |
925206-65-1 |
DC10006 |
RSV-604
Featured
RSV604 is a novel inhibitor of respiratory syncytial virus replication(EC50=0.86 uM); a putative RSV nucleoprotein(N) inhibitor in phase 2 clinical trials. |
676128-63-5 |